Prognostic impact of clinical trial eligibility in patients with advanced gastric cancer

Prognostic impact of clinical trial eligibility in patients with advanced gastric cancer

Abstract The CheckMate 649 trial demonstrated the clinical benefit of nivolumab plus chemotherapy in patients with human epidermal growth factor receptor 2 (HER2)-negative advanced gastric cancer. However, the background discrepancy between clinical practice and randomized controlled trials may impa...

Full description

Saved in:
Bibliographic Details
Main Authors: Takaaki Arigami, Daisuke Matsushita, Masataka Shimonosono, Yuki Hirase, Yusuke Tsuruda, Ken Sasaki, Kenji Baba, Yota Kawasaki, Takao Ohtsuka
Format: Article
Language:English
Published: Nature Portfolio 2025-03-01
Series:Scientific Reports
Subjects:
Clinical trials
Eligibility criteria
Tumor response
Prognosis
Advanced gastric cancer
Online Access:https://doi.org/10.1038/s41598-025-95501-0
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items